Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2010 /
Exemestane potential for hormone-receptor positive, early-stage breast cancer in the adjuvant setting

8th - 12th Dec 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.01.11
Views: 4737

Dr Leif Ellisen - Massachusetts General Hospital, Boston, USA

Dr Leif Ellisen updates ecancertv on exemestane and anastrozole providing similar control of breast cancer and survival with different side effect profiles. Interviewed at the 2010 San Antonio Breast Cancer Symposium, Dr Ellisen talks about how exemestane, an aromatase inhibitor that blocks production of oestrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer. He also discusses his work with circulating tumour cells.


Breast · Drug development · SABCS 2010

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation